{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:47:26Z","timestamp":1791895646018,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-HL007249"],"award-info":[{"award-number":["T32-HL007249"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01NS126752-01A1"],"award-info":[{"award-number":["1R01NS126752-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2BX005218"],"award-info":[{"award-number":["IK2BX005218"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX004868"],"award-info":[{"award-number":["I01BX004868"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Headache is a pain disorder present in populations world-wide with a higher incidence in females. Specifically, the incidences of medication overuse headache (MOH) have increased worldwide. Comorbidities of MOH include photosensitivity, anxiety, \u201cbrain fog\u201d, and decreased physical activity. The FDA-approved long-lasting selective \u03b2<jats:sub>2<\/jats:sub>-adrenergic receptor agonist, formoterol, is currently approved for use in severe asthma and chronic obstructive pulmonary disease. Recently, interest in repurposing formoterol for use in other disorders including Alzheimer\u2019s disease, and neuropathic pain after spinal cord injury and traumatic brain injury has gained traction. Thus, revisiting known side-effects of formoterol, like headache and anxiety, could inform treatment paradigms. The endocannabinoid (eCB) system is implicated in the etiology of preclinical headache, with observed decreases in the circulating levels of endogenous cannabinoids, referred to as Clinical Endocannabinoid Deficiency. As cross-talk between the eCB system and adrenergic receptors has been reported, this study investigated the role of the eCB system and ability of formoterol to induce headache-like periorbital allodynic behavior.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Female 8-week-old C57Bl\/6J mice were treated daily with formoterol (0.3 mg\/kg, i.p.) for up to 42-days, during which they were assessed for periorbital allodynia, open field\/novel object recognition, and photosensitivity. At the end of the study, the periaqueductal grey (PAG), a brain region known to contribute to both headache induction and maintenance, was collected and subjected to LC-MS to quantify endocannabinoid levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mice exhibited periorbital allodynia at nearly all time points tested and photosensitivity from 28-days onward. Levels of endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), along with cannabinoid receptor 1 (CB<jats:sub>1<\/jats:sub>R) expression were altered by both age and upon treatment with formoterol. Administration of FAAH\/MAGL inhibitors, to target the eCB system, and a non-selective cannabinoid receptor agonist, WIN 55,212 reversed the formoterol-induced periorbital allodynia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results suggest that formoterol is dysregulates eCB tone to drive headache-like periorbital allodynic behaviors. These results could help inform preventative treatment options for individuals receiving formoterol, as well as provide information on the interaction between the eCB and adrenergic system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01907-y","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T11:16:32Z","timestamp":1732014992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Formoterol dynamically alters endocannabinoid tone in the periaqueductal gray inducing headache"],"prefix":"10.1186","volume":"25","author":[{"given":"Ingrid L.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Liktor-Busa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Karlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Scholpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick G.","family":"Schnellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tally M.","family":"Largent-Milnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"5","key":"1907_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0301-0082(00)00010-1","volume":"62","author":"PJ Goadsby","year":"2000","unstructured":"Goadsby PJ (2000) The pharmacology of headache. Prog Neurobiol 62(5):509\u2013525","journal-title":"Prog Neurobiol"},{"issue":"4","key":"1907_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD et al (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23(4):344\u2013381","journal-title":"Lancet Neurol"},{"issue":"1","key":"1907_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ et al (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23(1):34","journal-title":"J Headache Pain"},{"issue":"4","key":"1907_CR4","doi-asserted-by":"publisher","first-page":"e2790","DOI":"10.1097\/GOX.0000000000002790","volume":"8","author":"HZ Law","year":"2020","unstructured":"Law HZ et al (2020) Hospital Burden of Migraine in United States Adults: A 15-year National Inpatient Sample Analysis. Plast Reconstr Surg Glob Open 8(4):e2790","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"1907_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fnins.2018.00172","volume":"12","author":"R Greco","year":"2018","unstructured":"Greco R et al (2018) Endocannabinoid System and Migraine Pain: An Update. Front Neurosci 12:172","journal-title":"Front Neurosci"},{"issue":"1","key":"1907_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S et al (2023) Medication overuse headache. Nat Rev Dis Primers 9(1):5","journal-title":"Nat Rev Dis Primers"},{"key":"1907_CR7","unstructured":"Fischer MA, Jan A (2023) Medication-Overuse Headache, in StatPearls. StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC.: Treasure Island (FL)"},{"issue":"2","key":"1907_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098614522683","volume":"5","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen ES, Lundqvist C (2014) Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 5(2):87\u201399","journal-title":"Ther Adv Drug Saf"},{"key":"1907_CR9","doi-asserted-by":"publisher","first-page":"1194134","DOI":"10.3389\/fpain.2023.1194134","volume":"4","author":"YT Kebede","year":"2023","unstructured":"Kebede YT et al (2023) Medication overuse headache: a review of current evidence and management strategies. Front Pain Res (Lausanne) 4:1194134","journal-title":"Front Pain Res (Lausanne)"},{"key":"1907_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-016-0629-6","volume":"17","author":"SM Llop","year":"2016","unstructured":"Llop SM et al (2016) Increased prevalence of depression and anxiety in patients with migraine and interictal photophobia. J Headache Pain 17:34","journal-title":"J Headache Pain"},{"issue":"9","key":"1907_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11910-018-0864-0","volume":"18","author":"A Albilali","year":"2018","unstructured":"Albilali A, Dilli E (2018) Photophobia: When Light Hurts, a Review. Curr Neurol Neurosci Rep 18(9):62","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"1907_CR12","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1007\/s00415-022-11080-4","volume":"269","author":"Y Wang","year":"2022","unstructured":"Wang Y et al (2022) Photophobia in headache disorders: characteristics and potential mechanisms. J Neurol 269(8):4055\u20134067","journal-title":"J Neurol"},{"issue":"1","key":"1907_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13293-021-00402-2","volume":"12","author":"A Levine","year":"2021","unstructured":"Levine A et al (2021) Sex differences in the expression of the endocannabinoid system within V1M cortex and PAG of Sprague Dawley rats. Biol Sex Differ 12(1):60","journal-title":"Biol Sex Differ"},{"issue":"1","key":"1907_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1210\/er.2005-0009","volume":"27","author":"U Pagotto","year":"2006","unstructured":"Pagotto U et al (2006) The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance. Endocr Rev 27(1):73\u2013100","journal-title":"Endocr Rev"},{"key":"1907_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-3-319-20825-1_6","volume":"231","author":"GA Cabral","year":"2015","unstructured":"Cabral GA, Ferreira GA, Jamerson MJ (2015) Endocannabinoids and the Immune System in Health and Disease. Handb Exp Pharmacol 231:185\u2013211","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"1907_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.phrs.2009.03.019","volume":"60","author":"R Pandey","year":"2009","unstructured":"Pandey R et al (2009) Endocannabinoids and immune regulation. Pharmacol Res 60(2):85\u201392","journal-title":"Pharmacol Res"},{"issue":"6","key":"1907_CR17","first-page":"607","volume":"6","author":"HC Lu","year":"2021","unstructured":"Lu HC, Mackie K (2021) Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging 6(6):607\u2013615","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"6","key":"1907_CR18","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/sj.npp.1301246","volume":"32","author":"P Sarchielli","year":"2007","unstructured":"Sarchielli P et al (2007) Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 32(6):1384\u20131390","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"1907_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd1495","volume":"3","author":"V Di Marzo","year":"2004","unstructured":"Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3(9):771\u2013784","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1907_CR20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/s41401-020-0385-7","volume":"41","author":"S-y Ren","year":"2020","unstructured":"Ren S-y et al (2020) Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases\u2014focusing on FAAH\/MAGL inhibitors. Acta Pharmacol Sin 41(10):1263\u20131271","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"1907_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/0269881111408958","volume":"26","author":"S Ruehle","year":"2012","unstructured":"Ruehle S et al (2012) The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 26(1):23\u201339","journal-title":"J Psychopharmacol"},{"key":"1907_CR22","doi-asserted-by":"publisher","first-page":"8332","DOI":"10.1007\/s12035-016-0313-5","volume":"54","author":"M Kruk-Slomka","year":"2017","unstructured":"Kruk-Slomka M et al (2017) Endocannabinoid system: the direct and indirect involvement in the memory and learning processes\u2014a short review. Mol Neurobiol 54:8332\u20138347","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1907_CR23","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.00100.2014","volume":"307","author":"C Lipina","year":"2014","unstructured":"Lipina C, Irving AJ, Hundal HS (2014) Mitochondria: a possible nexus for the regulation of energy homeostasis by the endocannabinoid system? Am J Physiology-Endocrinology Metabolism 307(1):E1\u2013E13","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"issue":"1","key":"1907_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/glia.24172","volume":"71","author":"A Bernal-Chico","year":"2023","unstructured":"Bernal-Chico A et al (2023) Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells. Glia 71(1):103\u2013126","journal-title":"Glia"},{"key":"1907_CR25","doi-asserted-by":"publisher","first-page":"615028","DOI":"10.3389\/fphar.2020.615028","volume":"11","author":"A Levine","year":"2020","unstructured":"Levine A et al (2020) DAGL\u03b1 Inhibition as a Non-invasive and Translational Model of Episodic Headache. Front Pharmacol 11:615028","journal-title":"Front Pharmacol"},{"key":"1907_CR26","doi-asserted-by":"publisher","first-page":"1171188","DOI":"10.3389\/fpain.2023.1171188","volume":"4","author":"E Liktor-Busa","year":"2023","unstructured":"Liktor-Busa E et al (2023) ABHD6 and MAGL control 2-AG levels in the PAG and allodynia in a CSD-induced periorbital model of headache. Front Pain Res (Lausanne) 4:1171188","journal-title":"Front Pain Res (Lausanne)"},{"key":"1907_CR27","doi-asserted-by":"crossref","unstructured":"Greco R et al (2021) Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine. Cells, 10(10)","DOI":"10.3390\/cells10102543"},{"key":"1907_CR28","doi-asserted-by":"crossref","unstructured":"Della Pietra A, Giniatullin R, Savinainen JR (2021) Distinct Activity of Endocannabinoid-Hydrolyzing Enzymes MAGL and FAAH in Key Regions of Peripheral and Central Nervous System Implicated in Migraine. Int J Mol Sci, 22(3)","DOI":"10.3390\/ijms22031204"},{"issue":"9","key":"1907_CR29","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1592\/phco.22.13.1129.33523","volume":"22","author":"M Friedman","year":"2002","unstructured":"Friedman M, Della Cioppa G, Kottakis J (2002) Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature. Pharmacotherapy 22(9):1129\u20131139","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1907_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00003495-199855020-00016","volume":"55","author":"RA Bartow","year":"1998","unstructured":"Bartow RA, Brogden RN (1998) Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 55(2):303\u2013322","journal-title":"Drugs"},{"issue":"3","key":"1907_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.biopsych.2013.05.024","volume":"75","author":"V Dang","year":"2014","unstructured":"Dang V et al (2014) Formoterol, a long-acting \u03b22 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry 75(3):179\u2013188","journal-title":"Biol Psychiatry"},{"key":"1907_CR32","doi-asserted-by":"publisher","first-page":"103956","DOI":"10.1016\/j.mcn.2024.103956","volume":"130","author":"M Erdem","year":"2024","unstructured":"Erdem M et al (2024) \u03b22-adrenoceptor agonist formoterol attenuates NLRP3 inflammasome activation and GSDMD-mediated pyroptosis in microglia through enhancing I\u03baB\u03b1\/NF-\u03baB inhibition, SQSTM1\/p62-dependent selective autophagy and ESCRT-III-mediated plasma membrane repair. Mol Cell Neurosci 130:103956","journal-title":"Mol Cell Neurosci"},{"key":"1907_CR33","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fnmol.2019.00324","volume":"12","author":"RA Ceredig","year":"2019","unstructured":"Ceredig RA et al (2019) Peripheral Delta Opioid Receptors Mediate Formoterol Anti-allodynic Effect in a Mouse Model of Neuropathic Pain. Front Mol Neurosci 12:324","journal-title":"Front Mol Neurosci"},{"key":"1907_CR34","doi-asserted-by":"publisher","first-page":"174480692091293","DOI":"10.1177\/1744806920912931","volume":"16","author":"M Kremer","year":"2020","unstructured":"Kremer M et al (2020) Delta opioid receptors are essential to the antiallodynic action of \u0392(2)-mimetics in a model of neuropathic pain. Mol Pain 16:1744806920912931","journal-title":"Mol Pain"},{"key":"1907_CR35","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.124.002171","volume-title":"Formoterol alters chemokine expression and ameliorates pain behaviors after moderate spinal cord injury in female mice","author":"IL Peterson","year":"2024","unstructured":"Peterson IL et al (2024) Formoterol alters chemokine expression and ameliorates pain behaviors after moderate spinal cord injury in female mice. Journal of Pharmacology and Experimental Therapeutics"},{"key":"1907_CR36","doi-asserted-by":"publisher","first-page":"114494","DOI":"10.1016\/j.expneurol.2023.114494","volume":"368","author":"NE Scholpa","year":"2023","unstructured":"Scholpa NE (2023) Role of DNA methylation during recovery from spinal cord injury with and without \u03b22-adrenergic receptor agonism. Exp Neurol 368:114494","journal-title":"Exp Neurol"},{"key":"1907_CR37","doi-asserted-by":"publisher","first-page":"112331","DOI":"10.1016\/j.biopha.2021.112331","volume":"144","author":"N Chen","year":"2021","unstructured":"Chen N et al (2021) \u03b22-adrenoreceptor agonist ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of mitochondrial biogenesis. Biomed Pharmacother 144:112331","journal-title":"Biomed Pharmacother"},{"key":"1907_CR38","doi-asserted-by":"crossref","unstructured":"Damo E, Agarwal A, Simonetti M (2023) Activation of \u03b22-Adrenergic Receptors in Microglia Alleviates Neuropathic Hypersensitivity in Mice. Cells, 12(2)","DOI":"10.3390\/cells12020284"},{"key":"1907_CR39","doi-asserted-by":"publisher","first-page":"p113064","DOI":"10.1016\/j.expneurol.2019.113064","volume":"322","author":"NE Scholpa","year":"2019","unstructured":"Scholpa NE et al (2019) \u03b2(2)-adrenergic receptor-mediated mitochondrial biogenesis improves skeletal muscle recovery following spinal cord injury. Exp Neurol 322:p113064","journal-title":"Exp Neurol"},{"key":"1907_CR40","doi-asserted-by":"publisher","first-page":"115436","DOI":"10.1016\/j.bcp.2023.115436","volume":"209","author":"KH Cleveland","year":"2023","unstructured":"Cleveland KH, Schnellmann RG (2023) The \u03b22-adrenergic receptor agonist formoterol restores mitochondrial homeostasis in glucose-induced renal proximal tubule injury through separate integrated pathways. Biochem Pharmacol 209:115436","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"1907_CR41","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.nmd.2012.06.157","volume":"22","author":"M Jourdain","year":"2012","unstructured":"Jourdain M et al (2012) TP 11 Effect of formoterol, a selective \u03b22 adrenoceptor agonist, against nerve injury-induced muscle disuse atrophy. Neuromuscul Disord 22(9):849\u2013850","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"1907_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/jamp.2012.0977","volume":"26","author":"AH Mansur","year":"2013","unstructured":"Mansur AH, Kaiser K (2013) Long-term safety and efficacy of fluticasone\/formoterol combination therapy in asthma. J Aerosol Med Pulm Drug Deliv 26(4):190\u2013199","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"4","key":"1907_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF03256622","volume":"1","author":"SM Cheer","year":"2002","unstructured":"Cheer SM, Scott LJ (2002) Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med 1(4):285\u2013300","journal-title":"Am J Respir Med"},{"key":"1907_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbr.2015.12.017","volume":"300","author":"M Nasehi","year":"2016","unstructured":"Nasehi M et al (2016) Modulation of cannabinoid signaling by amygdala \u03b12-adrenergic system in fear conditioning. Behav Brain Res 300:114\u2013122","journal-title":"Behav Brain Res"},{"key":"1907_CR45","doi-asserted-by":"publisher","first-page":"136363","DOI":"10.1016\/j.neulet.2021.136363","volume":"768","author":"M Jankovic","year":"2022","unstructured":"Jankovic M et al (2022) Sex specific effects of the fatty acid amide hydrolase inhibitor URB597 on memory and brain \u03b2(2)-adrenergic and D1-dopamine receptors. Neurosci Lett 768:136363","journal-title":"Neurosci Lett"},{"issue":"16","key":"1907_CR46","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1002\/jnr.22158","volume":"87","author":"BA Reyes","year":"2009","unstructured":"Reyes BA et al (2009) Cannabinoid modulation of cortical adrenergic receptors and transporters. J Neurosci Res 87(16):3671\u20133678","journal-title":"J Neurosci Res"},{"key":"1907_CR47","doi-asserted-by":"crossref","unstructured":"Zou S, Kumar U (2018) Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci, 19(3)","DOI":"10.3390\/ijms19030833"},{"key":"1907_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.irn.2015.10.001","volume":"125","author":"CJ Hillard","year":"2015","unstructured":"Hillard CJ (2015) The Endocannabinoid Signaling System in the CNS: A Primer. Int Rev Neurobiol 125:1\u201347","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"1907_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/ph16030345","volume":"16","author":"FK Alswailmi","year":"2023","unstructured":"Alswailmi FK (2023) A Cross Talk between the Endocannabinoid System and Different Systems Involved in the Pathogenesis of Hypertensive Retinopathy. Pharmaceuticals 16(3):345","journal-title":"Pharmaceuticals"},{"issue":"1\u20132","key":"1907_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pain.2005.07.008","volume":"118","author":"D Pascual","year":"2005","unstructured":"Pascual D et al (2005) A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118(1\u20132):23\u201334","journal-title":"Pain"},{"issue":"6","key":"1907_CR51","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1177\/01926233211010444","volume":"49","author":"M van Heerden","year":"2021","unstructured":"van Heerden M et al (2021) Exacerbation of Background Nuclear Cataracts in Sprague-Dawley Rats in Embryo-Fetal Development Studies With JNJ-42165279, a Fatty Acid Amide Hydrolase Inhibitor. Toxicol Pathol 49(6):1193\u20131205","journal-title":"Toxicol Pathol"},{"key":"1907_CR52","doi-asserted-by":"crossref","unstructured":"Mason BN et al Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache. J Vis Exp, 2021(173).","DOI":"10.3791\/62867"},{"key":"1907_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fncir.2016.00060","volume":"10","author":"A Matynia","year":"2016","unstructured":"Matynia A et al (2016) Peripheral sensory neurons expressing melanopsin respond to light. Front Neural Circuits 10:60","journal-title":"Front Neural Circuits"},{"key":"1907_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.mad.2015.08.005","volume":"150","author":"A Piyanova","year":"2015","unstructured":"Piyanova A et al (2015) Age-related changes in the endocannabinoid system in the mouse hippocampus. Mech Ageing Dev 150:55\u201364","journal-title":"Mech Ageing Dev"},{"key":"1907_CR55","doi-asserted-by":"crossref","unstructured":"Nidadavolu P et al (2022) Dynamic Changes in the Endocannabinoid System during the Aging Process: Focus on the Middle-Age Crisis. Int J Mol Sci, 23(18)","DOI":"10.3390\/ijms231810254"},{"issue":"1","key":"1907_CR56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/npp.2017.130","volume":"43","author":"CJ Hillard","year":"2018","unstructured":"Hillard CJ (2018) Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology 43(1):155\u2013172","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1907_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1124\/jpet.115.229971","volume":"357","author":"JL Wilkerson","year":"2016","unstructured":"Wilkerson JL et al (2016) The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther 357(1):145\u2013156","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1907_CR58","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.pnpbp.2005.04.027","volume":"29","author":"EH Kang","year":"2005","unstructured":"Kang EH, Yu BH (2005) Anxiety and beta-adrenergic receptor function in a normal population. Prog Neuropsychopharmacol Biol Psychiatry 29(5):733\u2013737","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"1907_CR59","first-page":"1251","volume":"54","author":"SB Munksgaard","year":"2014","unstructured":"Munksgaard SB, Jensen RH (2014) Medication overuse headache Headache 54(7):1251\u20131257","journal-title":"Medication overuse headache Headache"},{"key":"1907_CR60","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1111\/j.1526-4610.2006.00559.x","volume":"46","author":"SM Baskin","year":"2006","unstructured":"Baskin SM, Lipchik GL, Smitherman TA (2006) Mood and anxiety disorders in chronic headache. Headache 46:S76\u201387","journal-title":"Headache"},{"issue":"Suppl 1","key":"1907_CR61","first-page":"S379","volume":"153","author":"E Kelly","year":"2008","unstructured":"Kelly E, Bailey CP, Henderson G (2008) Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 153(Suppl 1):S379\u2013S388","journal-title":"Br J Pharmacol"},{"issue":"5","key":"1907_CR62","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.kint.2022.05.032","volume":"102","author":"EL Vallorz","year":"2022","unstructured":"Vallorz EL et al (2022) Kidney targeting of formoterol containing polymeric nanoparticles improves recovery from ischemia reperfusion-induced acute kidney injury in mice. Kidney Int 102(5):1073\u20131089","journal-title":"Kidney Int"},{"key":"1907_CR63","doi-asserted-by":"publisher","first-page":"104866","DOI":"10.1016\/j.nbd.2020.104866","volume":"140","author":"HJ Vekaria","year":"2020","unstructured":"Vekaria HJ et al (2020) Formoterol, a \u03b2(2)-adrenoreceptor agonist, induces mitochondrial biogenesis and promotes cognitive recovery after traumatic brain injury. Neurobiol Dis 140:104866","journal-title":"Neurobiol Dis"},{"issue":"4","key":"1907_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/biology13040231","volume":"13","author":"J-C Chang","year":"2024","unstructured":"Chang J-C et al (2024) Formoterol Acting via \u03b22-Adrenoreceptor Restores Mitochondrial Dysfunction Caused by Parkinson\u2019s Disease-Related UQCRC1 Mutation and Improves Mitochondrial Homeostasis Including Dynamic and Transport. Biology 13(4):231","journal-title":"Biology"},{"issue":"2","key":"1907_CR65","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1378\/chest.114.2.411","volume":"114","author":"M Cazzola","year":"1998","unstructured":"Cazzola M et al (1998) Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 114(2):411\u2013415","journal-title":"Chest"},{"issue":"2","key":"1907_CR66","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s13760-017-0764-0","volume":"117","author":"N Dirican","year":"2017","unstructured":"Dirican N, Demirci S, Cakir M (2017) The relationship between migraine headache and asthma features. Acta Neurol Belg 117(2):531\u2013536","journal-title":"Acta Neurol Belg"},{"key":"1907_CR67","doi-asserted-by":"publisher","first-page":"114012","DOI":"10.1016\/j.bcp.2020.114012","volume":"179","author":"R Tan","year":"2020","unstructured":"Tan R et al (2020) Promises and challenges of biologics for severe asthma. Biochem Pharmacol 179:114012","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"1907_CR68","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1212\/WNL.59.7.1011","volume":"59","author":"V Limmroth","year":"2002","unstructured":"Limmroth V et al (2002) Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59(7):1011\u20131014","journal-title":"Neurology"},{"issue":"10","key":"1907_CR69","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"H-C Diener","year":"2016","unstructured":"Diener H-C et al (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Reviews Neurol 12(10):575\u2013583","journal-title":"Nat Reviews Neurol"},{"issue":"4","key":"1907_CR70","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(10)70008-9","volume":"9","author":"S Evers","year":"2010","unstructured":"Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9(4):391\u2013401","journal-title":"Lancet Neurol"},{"issue":"1","key":"1907_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0333102412467512","volume":"33","author":"JL Johnson","year":"2013","unstructured":"Johnson JL et al (2013) Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia 33(1):52\u201364","journal-title":"Cephalalgia"},{"issue":"4","key":"1907_CR72","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/head.12532","volume":"55","author":"HL Rossi","year":"2015","unstructured":"Rossi HL, Recober A (2015) Photophobia in primary headaches. Headache 55(4):600\u2013604","journal-title":"Headache"},{"issue":"7","key":"1907_CR73","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/head.12135","volume":"53","author":"GF Carvalho","year":"2013","unstructured":"Carvalho GF et al (2013) Influence of migraine and of migraine aura on balance and mobility\u2013a controlled study. Headache 53(7):1116\u20131122","journal-title":"Headache"},{"issue":"Suppl 1","key":"1907_CR74","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.3109\/09638288.2010.511687","volume":"32","author":"M Leonardi","year":"2010","unstructured":"Leonardi M et al (2010) Functioning and disability in migraine. Disabil Rehabil 32(Suppl 1):S23\u201332","journal-title":"Disabil Rehabil"},{"issue":"8","key":"1907_CR75","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11916-020-00869-5","volume":"24","author":"R Langdon","year":"2020","unstructured":"Langdon R et al (2020) Pediatric Migraine and Academics. Curr Pain Headache Rep 24(8):40","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1907_CR76","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s10194-018-0933-4","volume":"19","author":"D Vuralli","year":"2018","unstructured":"Vuralli D, Ayata C, Bolay H (2018) Cognitive dysfunction and migraine. J Headache Pain 19(1):109","journal-title":"J Headache Pain"},{"issue":"1","key":"1907_CR77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s10194-019-0963-6","volume":"20","author":"D Vuralli","year":"2019","unstructured":"Vuralli D et al (2019) Behavioral and cognitive animal models in headache research. J Headache Pain 20(1):11","journal-title":"J Headache Pain"},{"issue":"5","key":"1907_CR78","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/0333102418804157","volume":"39","author":"KM Nation","year":"2019","unstructured":"Nation KM et al (2019) Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. Cephalalgia 39(5):617\u2013625","journal-title":"Cephalalgia"},{"issue":"5","key":"1907_CR79","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/FBP.0000000000000382","volume":"29","author":"R Kandasamy","year":"2018","unstructured":"Kandasamy R et al (2018) Medication overuse headache following repeated morphine, but not\u2206 9-tetrahydrocannabinol administration in the female rat. Behav Pharmacol 29(5):469\u2013472","journal-title":"Behav Pharmacol"},{"issue":"10","key":"1907_CR80","first-page":"20","volume":"28","author":"DT Perspect","year":"2012","unstructured":"Perspect DT (2012) Manage drug-induced photosensitivity through prevention and discontinuation of the causative agent once an event has occurred. Drugs Therapy Perspect 28(10):20\u201323","journal-title":"Drugs Therapy Perspect"},{"issue":"5951","key":"1907_CR81","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/307551a0","volume":"307","author":"LJ Rubin","year":"1984","unstructured":"Rubin LJ, Nolte JF (1984) Modulation of the response of a photosensitive muscle by \u03b2-adrenergic regulation of cyclic AMP levels. Nature 307(5951):551\u2013553","journal-title":"Nature"},{"issue":"1","key":"1907_CR82","first-page":"19","volume":"19","author":"GA Hofmann","year":"2021","unstructured":"Hofmann GA, Weber B (2021) Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences. J Dtsch Dermatol Ges 19(1):19\u201329","journal-title":"J Dtsch Dermatol Ges"},{"key":"1907_CR83","doi-asserted-by":"crossref","unstructured":"Lowe H et al (2021) The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. Int J Mol Sci, 22(17)","DOI":"10.3390\/ijms22179472"},{"key":"1907_CR84","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fphys.2013.00396","volume":"4","author":"N Ferrara","year":"2014","unstructured":"Ferrara N et al (2014) \u03b2-adrenergic receptor responsiveness in aging heart and clinical implications. Front Physiol 4:396","journal-title":"Front Physiol"},{"key":"1907_CR85","doi-asserted-by":"crossref","unstructured":"Lo Castro F et al (2022) Clinical Evidence of Cannabinoids in Migraine: A Narrative Review. J Clin Med, 11(6)","DOI":"10.3390\/jcm11061479"},{"issue":"1","key":"1907_CR86","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41421-020-0176-9","volume":"6","author":"Y Zhang","year":"2020","unstructured":"Zhang Y et al (2020) Single-particle cryo-EM structural studies of the \u03b22AR\u2013Gs complex bound with a full agonist formoterol. Cell discovery 6(1):45","journal-title":"Cell discovery"},{"key":"1907_CR87","doi-asserted-by":"crossref","unstructured":"Forkuo GS (2014) The Role of the Canonical Beta-2 Adrenoceptor Gs Pathway in Development of the Asthma Phenotype in Murine Models.","DOI":"10.1096\/fasebj.27.1_supplement.1107.17"},{"issue":"1","key":"1907_CR88","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2007.06.013","volume":"572","author":"KA Araya","year":"2007","unstructured":"Araya KA, Mahana CDP, Gonz\u00e1lez LG (2007) Role of cannabinoid CB1 receptors and Gi\/o protein activation in the modulation of synaptosomal Na+, K+-ATPase activity by WIN55, 212-2 and\u25b5 9-THC. Eur J Pharmacol 572(1):32\u201339","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1907_CR89","doi-asserted-by":"publisher","first-page":"L461","DOI":"10.1152\/ajplung.1994.266.4.L461","volume":"266","author":"P Baluk","year":"1994","unstructured":"Baluk P, McDonald DM (1994) The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiology-Lung Cell Mol Physiol 266(4):L461\u2013L468","journal-title":"Am J Physiology-Lung Cell Mol Physiol"},{"issue":"3","key":"1907_CR90","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.anai.2011.06.006","volume":"107","author":"BE Sekerel","year":"2011","unstructured":"Sekerel BE et al (2011) The effects of inhaled formoterol on the autonomic nervous system in adolescents with asthma. Ann Allergy Asthma Immunol 107(3):266\u2013272","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1907_CR91","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1476-5381.2010.00643.x","volume":"160","author":"G Bagdy","year":"2010","unstructured":"Bagdy G et al (2010) Headache-type adverse effects of NO donors: vasodilation and beyond. Br J Pharmacol 160(1):20\u201335","journal-title":"Br J Pharmacol"},{"key":"1907_CR92","doi-asserted-by":"publisher","first-page":"104866","DOI":"10.1016\/j.nbd.2020.104866","volume":"140","author":"HJ Vekaria","year":"2020","unstructured":"Vekaria HJ et al (2020) Formoterol, a \u03b22-adrenoreceptor agonist, induces mitochondrial biogenesis and promotes cognitive recovery after traumatic brain injury. Neurobiol Dis 140:104866","journal-title":"Neurobiol Dis"},{"issue":"7","key":"1907_CR93","doi-asserted-by":"publisher","first-page":"H785","DOI":"10.1152\/ajpheart.00571.2015","volume":"310","author":"Z Beny\u00f3","year":"2016","unstructured":"Beny\u00f3 Z et al (2016) Endocannabinoids in cerebrovascular regulation. Am J Physiol Heart Circ Physiol 310(7):H785\u2013801","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"1907_CR94","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1177\/0333102411410082","volume":"31","author":"P Jonsson","year":"2011","unstructured":"Jonsson P, Hedenrud T, Linde M (2011) Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia 31(9):1015\u20131022","journal-title":"Cephalalgia"},{"key":"1907_CR95","doi-asserted-by":"crossref","unstructured":"Chowdhury NU et al (2021) Sex and gender in asthma. Eur Respir Rev, 30(162)","DOI":"10.1183\/16000617.0067-2021"},{"issue":"4","key":"1907_CR96","first-page":"963","volume":"10","author":"CR Jenkins","year":"2022","unstructured":"Jenkins CR et al (2022) Personalized treatment of asthma: the importance of sex and gender differences. J Allergy Clin Immunology: Pract 10(4):963\u2013971e3","journal-title":"J Allergy Clin Immunology: Pract"},{"issue":"9","key":"1907_CR97","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S0006-2952(03)00109-6","volume":"65","author":"G Ortar","year":"2003","unstructured":"Ortar G et al (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65(9):1473\u20131481","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"1907_CR98","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/brainsci11101323","volume":"11","author":"MS Neumeier","year":"2021","unstructured":"Neumeier MS et al (2021) Dealing with headache: sex differences in the burden of migraine-and tension-type headache. Brain Sci 11(10):1323","journal-title":"Brain Sci"},{"key":"1907_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","volume":"83","author":"GD Anderson","year":"2008","unstructured":"Anderson GD (2008) Gender differences in pharmacological response. Int Rev Neurobiol 83:1\u201310","journal-title":"Int Rev Neurobiol"},{"issue":"1\u20132","key":"1907_CR100","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jneuroim.2005.10.005","volume":"171","author":"I Fidan","year":"2006","unstructured":"Fidan I et al (2006) The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol 171(1\u20132):184\u2013188","journal-title":"J Neuroimmunol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01907-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01907-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01907-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T23:02:19Z","timestamp":1732057339000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01907-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1907"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01907-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}